THRESHOLD PHARMACEUTICALS

3705 Haven Ave, Menlo Park, California, United States

Clinical Trials

6 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

61.5%

Phase 2

19.2%

Phase 3

15.4%

Trial Status Distribution

Active, not recruiting

23.1%

Completed

38.5%

Terminated

23.1%

Unknown

15.4%

Clinical Trials

Trials sponsored by this organization (26)

Immunotherapy Study of Evofosfamide in Combination With Ipilimumab

Phase 1

Unknown

interventional

May 201769 participants

Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer

Phase 2

Terminated

interventional

Jun 2014265 participants

Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer

Phase 1

Terminated

interventional

Jan 201419 participants

A Cardiac Safety Study of TH-302 in Patients With Advanced Solid Tumors

Phase 1

Unknown

interventional

Nov 201340 participants

Clinical Trial testing TH-302 in combination with gemcitabine in combination in previously untreated patients with pancreatic cancer

Phase 1

Active, not recruiting

Jul 2013660 participants

Clinical Trial testing TH-302 in combination with gemcitabine in combination in previously untreated patients with pancreatic cancer

Phase 1

Active, not recruiting

May 2013660 participants

A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma

Phase 2

Terminated

interventional

May 201311 participants

Clinical Trial testing TH-302 in combination with gemcitabine in combination in previously untreated patients with pancreatic cancer

Phase 1

Active, not recruiting

Apr 2013660 participants

Page 1 of 4

Approvals

No approval data available

News

No news articles found

Back to Organizations